Scholarlink

Background <p>Esketamine and remimazolam co-administration presents a viable opioid-free anesthetic alternative for outpatient hysteroscopy. This study was designed to ascertain the ED<sub>90</sub> of esketamine for inhibiting intraoperative movement responses in patients undergoing ambulatory hysteroscopy.</p> Methods <p>From February 2024 to May 2024, 50 patients undergoing ambulatory hysteroscopy were enrolled. An anesthetic regimen combining esketamine and remimazolam with 50&#xa0;mg flurbiprofen axetil was employed. The initial esketamine dose was 0.3&#xa0;mg/kg, with subsequent doses determined using a biased-coin design (9:1). The primary endpoint was the ED<sub>90</sub> of esketamine for inhibiting movement responses. Secondary outcomes included anesthesia recovery time, Visual Analog Scale (VAS) scores, and adverse events.</p> Results <p>The ED<sub>90</sub> of esketamine was 0.405&#xa0;mg/kg (95% CI: 0.370–0.494). Mean anesthesia recovery time was 12.1 ± 2.0&#xa0;min. No respiratory depression, hypertension, hypotension, or bradycardia occurred. Mild dizziness was observed in 38% of patients; other adverse events (postoperative nausea and vomiting 4%, coughing 4%, hiccups 4%, transient diplopia 2%) resolved spontaneously. Postoperative VAS scores ranged from 0 to 4 at PACU admission (4% reporting 4), decreasing to 0–1 within four hours.</p> Conclusions <p>In ambulatory hysteroscopy under remimazolam-based anesthesia with preemptive analgesia using flurbiprofen axetil, the ED<sub>90</sub> of esketamine required to suppress intraoperative body movement was 0.405&#xa0;mg/kg (95% CI: 0.370–0.494).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The 90% effective dose (ED90) of esketamine for inhibiting responses to intraoperative motor stimulation during ambulatory hysteroscopy: a biased-coin up-and-down sequential allocation trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月14日

查看全文
  • Ruiqi Zhang,
  • Chen Wang,
  • Lin Wang,
  • Wenyue Kang,
  • Zhihua Wang

摘要

Background

Esketamine and remimazolam co-administration presents a viable opioid-free anesthetic alternative for outpatient hysteroscopy. This study was designed to ascertain the ED90 of esketamine for inhibiting intraoperative movement responses in patients undergoing ambulatory hysteroscopy.

Methods

From February 2024 to May 2024, 50 patients undergoing ambulatory hysteroscopy were enrolled. An anesthetic regimen combining esketamine and remimazolam with 50 mg flurbiprofen axetil was employed. The initial esketamine dose was 0.3 mg/kg, with subsequent doses determined using a biased-coin design (9:1). The primary endpoint was the ED90 of esketamine for inhibiting movement responses. Secondary outcomes included anesthesia recovery time, Visual Analog Scale (VAS) scores, and adverse events.

Results

The ED90 of esketamine was 0.405 mg/kg (95% CI: 0.370–0.494). Mean anesthesia recovery time was 12.1 ± 2.0 min. No respiratory depression, hypertension, hypotension, or bradycardia occurred. Mild dizziness was observed in 38% of patients; other adverse events (postoperative nausea and vomiting 4%, coughing 4%, hiccups 4%, transient diplopia 2%) resolved spontaneously. Postoperative VAS scores ranged from 0 to 4 at PACU admission (4% reporting 4), decreasing to 0–1 within four hours.

Conclusions

In ambulatory hysteroscopy under remimazolam-based anesthesia with preemptive analgesia using flurbiprofen axetil, the ED90 of esketamine required to suppress intraoperative body movement was 0.405 mg/kg (95% CI: 0.370–0.494).